Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.61 |
| ▸ | NPY2R | P49146 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.58 |
| ▸ | MC4R | P32245 | 2/20 | 0.57 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MC3R | P41968 | 2/20 | 0.57 |
| ▸ | MC1R | Q01726 | 2/20 | 0.57 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.57 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 3/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30816280 | 0.93 | NPY1R (0.65) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29883115 | 0.92 | C5AR1 (0.59) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30578735 | 0.92 | NPY2R (0.64) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29430205 | 0.92 | NPY1R (0.65) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30578728 | 0.90 | CXCR4 (0.66) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29531305 | 0.90 | CXCR4 (0.63) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30578720 | 0.89 | NPY1R (0.69) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29430200 | 0.88 | NPY2R (0.74) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL29523146 | 0.88 | RXFP1 (0.64) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL31183030 | 0.88 | NPY1R (0.67) | NPY1RNPY2RNPY4RNPY5RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | NPY1R 3197/4885NPY2R 4335/4885NPY4R 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.